Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

AOD-9604 Plateau & Non-Response Troubleshooting

By
Published Updated Last reviewed
11 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • What it is / a 16-amino-acid fragment of human growth hormone, hGH 177-191 plus an N-terminal tyrosine [3]
  • Largest human study / 24 weeks, 502 randomized, failed the primary weight-loss endpoint [1]
  • Approved dose / none; AOD-9604 is not an FDA-approved drug [1]
  • Best animal result / 19 days of oral dosing cut weight gain by more than half in obese rats [5]
  • Receptor finding / lipolytic action not mediated directly through beta-3 receptors in mice [6]
  • FDA safety note / serious adverse events possibly associated, causality not clear [7]
  • Compounding status / in FDA's nominated-but-withdrawn table with stated safety concerns [7]
  • Sport / WADA prohibits AOD-9604 at all times [8]

Is a plateau the right question?

A plateau means a response happened and then stopped. For AOD-9604 that first step is the problem. The main human obesity study failed its primary weight-loss endpoint and the sponsor dropped the program [1]. A 2026 review notes that this conclusion rests on sponsor-reported phase 2 results rather than peer-reviewed randomized trials, and that robust human data for visceral-fat reduction or other metabolic benefit are lacking [1].

What the animal data show

In obese Zucker rats, oral AOD9604 at 500 microgram/kg/day for 19 days reduced body-weight gain by more than half, 15.8 g versus 35.6 g in controls, with higher fat-tissue lipolytic activity and no adverse effect on insulin sensitivity by euglycemic clamp [5]. In obese mice, 14 days of intraperitoneal AOD9604 reduced body weight and body fat and raised beta-3 adrenergic receptor RNA [6].

Heffernan and colleagues concluded that the lipolytic actions of hGH and AOD9604 are not mediated directly through the beta-3 receptor, though both raise its expression, and the long-term effects did not appear in receptor knockout mice [6]. A beta-3 desensitization explanation for a human plateau is therefore an extrapolation, not a finding.

What can be checked

AOD-9604 is not an FDA-approved drug [1]. On FDA's page about bulk substances that may present significant safety risks in compounding, AOD-9604 sits in the nominated-but-withdrawn table. FDA cites immunogenicity risk for certain routes of administration, says it has identified no or only limited safety information, and states that it has identified serious adverse events that may be associated with AOD-9604, though causality is not clear [7]. Removal from category 2 was not a finding that it is safe [7].

AOD-9604 appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians [11][9], and it is not among the six peptides in HHS's draft enforcement-discretion policy [10].

What about dose, timing or cycling?

There is no approved dose. The 24-week human trial tested an oral candidate, and no efficacy trials of injected products were found, so seller protocols for dose, timing or cycling are not evidence-based recommendations [1].

Frequently asked questions

Why did AOD-9604 stop working for me?
An apparent plateau does not show that AOD-9604 caused the earlier weight change. The main human trial of an oral candidate failed its weight-loss endpoint [1].
Does AOD-9604 work through beta-3 receptors?
Not directly, according to the mouse study usually cited for the idea: Heffernan and colleagues concluded the lipolytic actions of hGH and AOD9604 are not mediated directly through the beta-3 receptor, though both raise receptor RNA levels [6].
Does AOD-9604 raise IGF-1?
Preclinical work found no growth-hormone-receptor binding, and human IGF-1 and body-composition data are too limited to say more [1].
Is AOD-9604 FDA-approved?
No. It was in development for obesity, with phase IIa trials underway by February 2002 [4], but it never reached approval and the obesity program was dropped [1].

References

  1. Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, RuchaŁa M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
  2. Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015;45(4):426-32. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model
  3. Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015;7(1):31-8. Detection and in vitro metabolism of AOD9604
  4. Wilding J. AOD-9604 Metabolic. Curr Opin Investig Drugs. 2004;5(4):436-40. AOD-9604 Metabolic
  5. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
  6. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-9. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
  7. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA
  8. World Anti-Doping Agency. 2026 Prohibited List. WADA 2026 Prohibited List
  9. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act | FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act | FDA
  10. HHS draft enforcement-discretion policy for compounding certain peptides, Federal Register document 2026-22192. Federal Register document 2026-22192
  11. FDA list of bulk drug substances for state-licensed pharmacies and physicians (category lists), updated May 14, 2026. FDA bulk drug substances list
Evidence overview for AOD-9604 Plateau & Non-Response Troubleshooting